NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT07020221 2026-03-09A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsVerastem, Inc.Phase 1/2 Recruiting295 enrolled
NCT06630325 2026-01-07A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic CancerOHSU Knight Cancer InstitutePhase 2 Active not recruiting30 enrolled